L8 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:675777 CAPLUS <<LOGINID::20080113>>
DOCUMENT NUMBER: 147:64481
TITLE: Methods of screening agents for activity using teleosts
INVENTOR(S): McGrath, Patricia; Parng, Chuenlei; Serbedzija, George N.
PATENT ASSIGNEE(S): Phylonix Pharmaceuticals, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 74pp., Cont.-in-part of U.S. Ser. No. 678,765.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 2007143865 | A1 | 20070621 | US 2006-515355 | 20060901 |
| US 6299858 | B1 | 20011009 | US 1999-255397 | 19990222 <-- |
| EP 1548123 | A1 | 20050629 | EP 2005-1508 | 19990222 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY | | | | |
| US 6656449 | B1 | 20031202 | US 2000-645432 | 20000823 <-- |
| US 2004062712 | A1 | 20040401 | US 2003-678765 | 20031002 <-- |
| US 2006104905 | A1 | 20060518 | US 2005-280849 | 20051115 |

PRIORITY APPLN. INFO.:

| | | |
|---|---|---|
| US 1998-75783P | P | 19980223 |
| US 1998-100950P | P | 19980918 |
| US 1999-255397 | A2 | 19990222 |
| US 2000-645432 | A1 | 20000823 |
| US 2003-678765 | A2 | 20031002 |
| EP 1999-934309 | A3 | 19990222 |
| US 2001-947635 | A1 | 20010905 |

ABSTRACT:
The present invention provides methods of screening an agent for activity using teleosts. Methods of screening an agent for angiogenesis activity, toxic activity and an effect cell death activity in teleosts are provided. Methods of screening an agent including a drug for an activity in the brain or central nervous system in zebrafish are provided. The invention further provides high throughput methods of screening agents in multi-well plates. Functional blood-brain barrier (BBB) was present in embryo zebrafish demonstrating it's usefulness for screening agents for BBB permeability.

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | US 2007143865 | A1 | 20070621 | US 2006-515355 | 20060901 |
| | US 6299858 | B1 | 20011009 | US 1999-255397 | 19990222 <-- |
| | EP 1548123 | A1 | 20050629 | EP 2005-1508 | 19990222 <-- |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY | | | | |
| | US 6656449 | B1 | 20031202 | US 2000-645432 | 20000823 <-- |
| | US 2004062712 | A1 | 20040401 | US 2003-678765 | 20031002 <-- |
| | US 2006104905 | A1 | 20060518 | US 2005-280849 | 20051115 |

IT ***50-02-2***, Dexamethasone 302-79-4, Retinoic acid 23110-15-8D, Fumagillin, derivative 629627-77-6, Ovicillin
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); BIOL (Biological study)
(methods of screening agents for activity using teleosts)
IT 50-81-7, Ascorbic acid, biological studies 53-06-5, Cortisone 59-02-9, α-Tocopherol 70-51-9, Deferoxamine 91-56-5, Isatin 348-67-4,

D-Methionine 452-86-8, 4-Methylcatechol 616-91-1, N-Acetyl-L-cysteine 700-06-1, Indole-3-carbinol 2323-36-6, Deprenyl 2682-49-7, 2-Oxothiazolidine 10118-90-8, Minocycline 27138-57-4 50903-99-6, L-NAME 57828-26-9, Lipoic acid
RL: PAC (Pharmacological activity); BIOL (Biological study)
(methods of screening agents for activity using teleosts)

IT 50-02-2, Dexamethasone
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); BIOL (Biological study)
(methods of screening agents for activity using teleosts)

RN 50-02-2 CAPLUS

CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11β,16α)- (CA INDEX NAME)

Absolute stereochemistry.




IT 700-06-1, Indole-3-carbinol
RL: PAC (Pharmacological activity); BIOL (Biological study)
(methods of screening agents for activity using teleosts)

RN 700-06-1 CAPLUS

CN 1H-Indole-3-methanol (CA INDEX NAME)




L8 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:376660 CAPLUS <<LOGINID::20080113>>

DOCUMENT NUMBER: 138:379207

TITLE: Improved use of antitumoral compound in cancer therapy

INVENTOR(S): Jimeno, Jose; Ruiz Casado, Ana; Lopez Lazaro, Luis; Rowinsky, Eric; Hidalgo, Manuel

PATENT ASSIGNEE(S): Pharmamar S.A., Spain

SOURCE: PCT Int. Appl., 28 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|

| | | | | | |
|---|---|---|---|---|---|
| WO 2003039571 | A1 | 20030515 | WO 2002-US33548 | | 20021021 <-- |
| W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | | |
| CA 2462502 | A1 | 20030515 | CA 2002-2462502 | | 20021021 <-- |
| AU 2002343548 | A1 | 20030519 | AU 2002-343548 | | 20021021 <-- |
| AU 2002343548 | B2 | 20071108 | | | |
| EP 1435988 | A1 | 20040714 | EP 2002-780496 | | 20021021 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | | | | |
| BR 2002013424 | A | 20041214 | BR 2002-13424 | | 20021021 <-- |
| HU 2004001903 | A2 | 20050128 | HU 2004-1903 | | 20021021 <-- |
| CN 1606449 | A | 20050413 | CN 2002-825666 | | 20021021 <-- |
| JP 2005509650 | T | 20050414 | JP 2003-541862 | | 20021021 <-- |
| RU 2306933 | C2 | 20070927 | RU 2004-115110 | | 20021021 <-- |
| MX 2004PA03674 | A | 20040723 | MX 2004-PA3674 | | 20040419 |
| IN 2004DN01070 | A | 20060728 | IN 2004-DN1070 | | 20040421 |
| NO 2004002035 | A | 20040518 | NO 2004-2035 | | 20040518 |
| US 2005004018 | A1 | 20050106 | US 2004-492320 | | 20040818 |
| PRIORITY APPLN. INFO.: | | | US 2001-348414P | P | 20011019 |
| | | | WO 2002-US33548 | W | 20021021 |

ABSTRACT:
Improved dosing schedules for ecteinascidin 743 are given for treatment of cancer.

| | PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|---|
| PI | WO 2003039571 | A1 | 20030515 | WO 2002-US33548 | | 20021021 <-- |
| | W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | | |
| | CA 2462502 | A1 | 20030515 | CA 2002-2462502 | | 20021021 <-- |
| | AU 2002343548 | A1 | 20030519 | AU 2002-343548 | | 20021021 <-- |
| | AU 2002343548 | B2 | 20071108 | | | |
| | EP 1435988 | A1 | 20040714 | EP 2002-780496 | | 20021021 <-- |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | | | | |
| | BR 2002013424 | A | 20041214 | BR 2002-13424 | | 20021021 <-- |
| | HU 2004001903 | A2 | 20050128 | HU 2004-1903 | | 20021021 <-- |
| | CN 1606449 | A | 20050413 | CN 2002-825666 | | 20021021 <-- |
| | JP 2005509650 | T | 20050414 | JP 2003-541862 | | 20021021 <-- |
| | RU 2306933 | C2 | 20070927 | RU 2004-115110 | | 20021021 <-- |
| | MX 2004PA03674 | A | 20040723 | MX 2004-PA3674 | | 20040419 |
| | IN 2004DN01070 | A | 20060728 | IN 2004-DN1070 | | 20040421 |
| | NO 2004002035 | A | 20040518 | NO 2004-2035 | | 20040518 |
| | US 2005004018 | A1 | 20050106 | US 2004-492320 | | 20040818 |

IT ***114899-77-3***, Ecteinascidin 743

RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(improved use of antitumoral compound in cancer therapy)

IT ***50-02-2*** 15663-27-1, Cisplatin 23214-92-8, Doxorubicin 33069-62-4, Paclitaxel
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(improved use of antitumoral compound in cancer therapy)

IT ***114899-77-3***, Ecteinascidin 743
RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(improved use of antitumoral compound in cancer therapy)

RN 114899-77-3 CAPLUS

CN Spiro[6,16-(epithiopropanoxymethano)-7,13-imino-12H-1,3-dioxolo[7,8]isoquino[3,2-b][3]benzazocine-20,1'(2'H)-isoquinolin]-19-one, 5-(acetyloxy)-3',4',6,6a,7,13,14,16-octahydro-6',8,14-trihydroxy-7',9-dimethoxy-4,10,23-trimethyl-, (1'R,6R,6aR,7R,13S,14S,16R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




IT ***50-02-2***
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(improved use of antitumoral compound in cancer therapy)

RN 50-02-2 CAPLUS

CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11β,16α)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:353292 CAPLUS <<LOGINID::20080113>>
DOCUMENT NUMBER: 136:350548
TITLE: Effective antitumor treatments with combinations of ET-743 with other antitumor agents resulting in additive and synergistic interactions
INVENTOR(S): Takahashi, Naoto; Weitman, Steve; D'incalci, Maurizio; Faicloth, Glynn Thomas; Giavazzi, Rafaella; Gescher, Andreas
PATENT ASSIGNEE(S): Pharma Mar, S.A., Spain
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|
| WO 2002036135 | A2 | 20020510 | WO 2001-GB4902 | | 20011106 <-- |
| WO 2002036135 | A3 | 20030410 | | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | | |
| CA 2428160 | A1 | 20020510 | CA 2001-2428160 | | 20011106 <-- |
| AU 200212499 | A | 20020515 | AU 2002-12499 | | 20011106 <-- |
| BR 2001015162 | A | 20031021 | BR 2001-15162 | | 20011106 <-- |
| EP 1365808 | A2 | 20031203 | EP 2001-980710 | | 20011106 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | | |
| JP 2004517056 | T | 20040610 | JP 2002-538946 | | 20011106 <-- |
| HU 2004000648 | A2 | 20040628 | HU 2004-648 | | 20011106 <-- |
| NZ 525730 | A | 20041224 | NZ 2001-525730 | | 20011106 <-- |
| NO 2003002027 | A | 20030704 | NO 2003-2027 | | 20030506 <-- |
| MX 2003PA03975 | A | 20040212 | MX 2003-PA3975 | | 20030506 <-- |
| ZA 2003003474 | A | 20040806 | ZA 2003-3474 | | 20030506 <-- |
| BG 107843 | A | 20040630 | BG 2003-107843 | | 20030523 <-- |
| US 2004108086 | A1 | 20040610 | US 2003-416086 | | 20030917 <-- |
| PRIORITY APPLN. INFO.: | | | US 2000-246233P | P | 20001106 |
| | | | US 2000-248095P | P | 20001113 |
| | | | US 2001-345982P | P | 20011019 |
| | | | WO 2001-GB4902 | W | 20011106 |

ABSTRACT:
ET-743 is used in the preparation of a medicament for an effective treatment of a tumor by combination therapy employing ET-743 with another drug.

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI WO 2002036135 | A2 | 20020510 | WO 2001-GB4902 | 20011106 <-- |

WO 2002036135 A3 20030410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

| | | | | |
|---|---|---|---|---|
| CA 2428160 | A1 | 20020510 | CA 2001-2428160 | 20011106 <-- |
| AU 200212499 | A | 20020515 | AU 2002-12499 | 20011106 <-- |
| BR 2001015162 | A | 20031021 | BR 2001-15162 | 20011106 <-- |
| EP 1365808 | A2 | 20031203 | EP 2001-980710 | 20011106 <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| JP 2004517056 | T | 20040610 | JP 2002-538946 | 20011106 <-- |
| HU 2004000648 | A2 | 20040628 | HU 2004-648 | 20011106 <-- |
| NZ 525730 | A | 20041224 | NZ 2001-525730 | 20011106 <-- |
| NO 2003002027 | A | 20030704 | NO 2003-2027 | 20030506 <-- |
| MX 2003PA03975 | A | 20040212 | MX 2003-PA3975 | 20030506 <-- |
| ZA 2003003474 | A | 20040806 | ZA 2003-3474 | 20030506 <-- |
| BG 107843 | A | 20040630 | BG 2003-107843 | 20030523 <-- |
| US 2004108086 | A1 | 20040610 | US 2003-416086 | 20030917 <-- |

IT ***114899-77-3***, ET-743
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(effective antitumor treatments with combinations of ET-743 with other antitumor agents resulting in additive and synergistic interactions)

IT ***50-02-2***, Dexamethasone
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hepatoprotectant; effective antitumor treatments with combinations of ET-743 with other antitumor agents resulting in additive and synergistic interactions)

IT ***114899-77-3***, ET-743
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(effective antitumor treatments with combinations of ET-743 with other antitumor agents resulting in additive and synergistic interactions)

RN 114899-77-3 CAPLUS

CN Spiro[6,16-(epithiopropanoxymethano)-7,13-imino-12H-1,3-dioxolo[7,8]isoquino[3,2-b][3]benzazocine-20,1'(2'H)-isoquinolin]-19-one, 5-(acetyloxy)-3',4',6,6a,7,13,14,16-octahydro-6',8,14-trihydroxy-7',9-dimethoxy-4,10,23-trimethyl-, (1'R,6R,6aR,7R,13S,14S,16R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




IT *50-02-2*, Dexamethasone
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hepatoprotectant; effective antitumor treatments with combinations of ET-743 with other antitumor agents resulting in additive and synergistic interactions)
RN 50-02-2 CAPLUS
CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11β,16α)- (CA INDEX NAME)

Absolute stereochemistry.




L8 ANSWER 4 OF 5 USPATFULL on STN
ACCESSION NUMBER: 2005:4912 USPATFULL <<LOGINID::20080113>>
TITLE: Use of antitumoral compound in cancer therapy
INVENTOR(S): Jimeno, Jose, Madrid, SPAIN
Casado, Ana Ruiz, Madrid, SPAIN
Lazaro, Luis Lopez, Madrid, SPAIN
Rowensky, Eric, San Antonio, TX, UNITED STATES
Hidalgo, Manuel, Baltimore, MD, UNITED STATES

| | NUMBER | KIND | DATE | | |
|---|---|---|---|---|---|
| PATENT INFORMATION: | US 2005004018 | A1 | 20050106 | | |
| APPLICATION INFO.: | US 2004-492320 | A1 | 20040818 | (10) | <-- |

WO 2002-US33548 20021021 <--

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 2001-348414P | 20011019 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FISH & RICHARDSON PC, 225 FRANKLIN ST, BOSTON, MA, 02110
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
LINE COUNT: 675
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ABSTRACT:

Improved dosing schedules for ecteinascidin 743 are given for treatment of cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AI US 2004-492320 A1 20040818 (10) <--
20021021
IT ***114899-77-3***, Ecteinascidin 743
(improved use of antitumoral compound in cancer therapy)
IT ***50-02-2*** 15663-27-1, Cisplatin 23214-92-8, Doxorubicin
33069-62-4, Paclitaxel
(improved use of antitumoral compound in cancer therapy)
IT ***114899-77-3***, Ecteinascidin 743
(improved use of antitumoral compound in cancer therapy)
RN 114899-77-3 USPATFULL
CN Spiro[6,16-(epithiopropanoxymethano)-7,13-imino-12H-1,3-dioxolo[7,8]isoquino[3,2-b][3]benzazocine-20,1'(2'H)-isoquinolin]-19-one, 5-(acetyloxy)-3',4',6,6a,7,13,14,16-octahydro-6',8,14-trihydroxy-7',9-dimethoxy-4,10,23-trimethyl-, (1'R,6R,6aR,7R,13S,14S,16R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




IT ***50-02-2***
(improved use of antitumoral compound in cancer therapy)

RN 50-02-2 USPATFULL
CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11β,16α)- (CA INDEX NAME)

Absolute stereochemistry.




L8 ANSWER 5 OF 5 USPATFULL on STN

| | | | | |
|---|---|---|---|---|
| ACCESSION NUMBER: | 2004:142434 USPATFULL <<LOGINID::20080113>> | | | |
| TITLE: | Effective antitumor treatments | | | |
| INVENTOR(S): | Takahashi, Naoto, Tokyo, JAPAN<br>Weitman, Steve, San Antonio, TX, UNITED STATES<br>D'Incalci, Maurizio, Milan, ITALY<br>Faircloth, Glynn Thomas, Cambridge, MA, UNITED STATES<br>Giavazzi, Rafaella, Bergamo, ITALY<br>Gescher, Andreas, Woodhouse Eves, UNITED KINGDOM | | | |
| | NUMBER | KIND | DATE | |
| PATENT INFORMATION: | US 2004108086 | A1 | 20040610 | |
| APPLICATION INFO.: | US 2003-416086 | A1 | 20030917 (10) | <-- |
| | WO 2001-GB4902 | | 20011106 | <-- |
| DOCUMENT TYPE: | Utility | | | |
| FILE SEGMENT: | APPLICATION | | | |
| LEGAL REPRESENTATIVE: | BANNER & WITCOFF, LTD., 28 STATE STREET, 28th FLOOR, BOSTON, MA, 02109-9601 | | | |
| NUMBER OF CLAIMS: | 10 | | | |
| EXEMPLARY CLAIM: | 1 | | | |
| LINE COUNT: | 752 | | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ABSTRACT:

ET-743 is used in the preparation of a medicament for an effective treatment of a tumour by combination therapy employing ET-743 with another drug.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AI US 2003-416086 A1 20030917 (10) <--
20011106

IT ***114899-77-3***, ET-743
(effective antitumor treatments with combinations of ET-743 with other antitumor agents resulting in additive and synergistic interactions)

IT ***50-02-2***, Dexamethasone
(hepatoprotectant; effective antitumor treatments with combinations of ET-743 with other antitumor agents resulting in additive and synergistic interactions)

IT ***114899-77-3***, ET-743
(effective antitumor treatments with combinations of ET-743 with other

antitumor agents resulting in additive and synergistic interactions)

RN 114899-77-3 USPATFULL

CN Spiro[6,16-(epithiopropanoxymethano)-7,13-imino-12H-1,3-dioxolo[7,8]isoquino[3,2-b][3]benzazocine-20,1'(2'H)-isoquinolin]-19-one, 5-(acetyloxy)-3',4',6,6a,7,13,14,16-octahydro-6',8,14-trihydroxy-7',9-dimethoxy-4,10,23-trimethyl-, (1'R,6R,6aR,7R,13S,14S,16R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




IT *50-02-2*, Dexamethasone

(hepatoprotectant; effective antitumor treatments with combinations of ET-743 with other antitumor agents resulting in additive and synergistic interactions)

RN 50-02-2 USPATFULL

CN Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11β,16α)- (CA INDEX NAME)

Absolute stereochemistry.



```
=> d his

     (FILE 'HOME' ENTERED AT 21:04:11 ON 13 JAN 2008)

     FILE 'REGISTRY' ENTERED AT 21:04:22 ON 13 JAN 2008
                E ET 743/CN
L1            1 S E3
                E DEXAMETHASONE/CN
L2            1 S E15
                E INDOLE-3-CARBINOL/CN
L3            1 S E27

     FILE 'CAPLUS, USPATFULL, USPATOLD, USPAT2, MEDLINE' ENTERED AT 21:06:42
     ON 13 JAN 2008
L4            4 S L1 AND L3
L5           26 S L1 AND L2
L6            9 S L2 AND L3
L7           35 S L4 OR L5 OR L6
L8            5 S L7 AND AY<2004
L9          281 S L3 AND (HEPATOTOXIC? OR ?TOXIC?)
                SAV L8 C10575132/A
L10         116 S L9 AND CANCER
L11          20 S L10 AND AY<2004
L12           5 S L3 (L) HEPATOTOXICITY
L13           0 S L12 AND AY<2004
L14          67 S L3 (L) LIVER
L15           0 S L14 AND AY<2004
L16          61 S L14 AND PY<2004
L17           3 S L12 AND PY<2004
```